Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.35 |
| ▸ | CNR2 | P34972 | 8/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.32 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909746 | 0.82 | CCR2 (0.49) | CCR2KDM5ARIPK1SSTR4PDK1 | |
| SCHEMBL22280240 | 0.80 | SIGMAR1 (0.43) | CCR2KDM5ASSTR4SSTR1 | |
| SCHEMBL12208867 | 0.79 | ALDH1A1 (0.46) | CCR2PDK1PDK2PDK3PDK4 | |
| SCHEMBL18909861 | 0.78 | CCR2 (0.50) | CCR2CNR2PDK1PDK2PDK3 | |
| SCHEMBL25676636 | 0.78 | PDK1 (0.39) | PDK1PDK2PDK3PDK4ACSS2 | |
| SCHEMBL14114344 | 0.77 | PDK1 (0.56) | CCR2PDK1PDK2PDK3PDK4 | |
| SCHEMBL23169306 | 0.76 | PDK1 (0.42) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL14008106 | 0.75 | CCR2 (0.41) | CCR2KDM5ARIPK1CNR2SSTR4 | |
| SCHEMBL12334726 | 0.74 | EPHX1 (0.52) | CCR2KDM5ASSTR4PDK1PDK2 | |
| SCHEMBL13854074 | 0.74 | RIPK1 (0.40) | CCR2RIPK1CNR2CNR1ACSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10676479-B2 | Imidazolepyridine compounds and uses thereof | NOVARTIS AG (CH) | 2020-06-09 | — | — | US | disclosed |
| US-20190233426-A1 | IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233426-A1 | IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, BMI1 | CCR2 3172/4885KDM5A 84/4885RIPK1 1231/4885 |
| US-10676479-B2 | Imidazolepyridine compounds and uses thereof | EZH2, DOT1L, BMI1 | CCR2 3172/4885KDM5A 84/4885RIPK1 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.